

Synagis® (palivizumab)

When requesting Synagis® (palivizumab), the individual requiring treatment must be diagnosed with one of the following FDA-approved indications or approved compendial uses and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indications

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients with:

- A history of premature birth,
- Bronchopulmonary dysplasia (e.g., chronic lung disease),
- Hemodynamically significant congenital heart disease (CHD).

Approved Off-label Compendial Uses

Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients with:

- Congenital abnormality of the airway,
- A neuromuscular disorder,
- Immunocompromised status,
- A previous or upcoming cardiac transplantation.

Coverage Guidelines

The individual is requesting Synagis for the prevention of lower respiratory tract infection caused by respiratory syncytial virus (RSV).

Preterm infant

The individual must meet both of the following criteria for approval:

- Is born before 29 weeks, 0 days gestation (i.e., ≤ 28 weeks, 6 days gestation);
- Will be less than 12 months of age at the start of the RSV season.

Chronic lung disease of prematurity

The individual must meet all of the following criteria for approval:

- Is born before 32 weeks, 0 days gestation;
- Has required greater than 21% oxygen for at least the first 28 days after birth;
- Will be less than 12 months of age at the start of the RSV season OR will be less than 24 months of age at the start of the RSV season and has required medical therapy (e.g., chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) during the 6-month period before the start of the second RSV season.

Congenital heart disease (CHD)

The individual must meet all of the following criteria for approval:

- Will be less than 12 months of age at the start of the RSV season;
- Synagis is prescribed by or in consultation with a cardiologist or intensivist;
- Has at least one of the following conditions:
 - o Has hemodynamically significant cyanotic CHD;
 - o Has acyanotic heart disease and is receiving medication to control heart failure and will require cardiac surgical procedures;
 - o Has lesions that have been adequately corrected by surgery and continues to require medication for congestive heart failure;
 - o Has moderate to severe pulmonary hypertension.

Anatomic Pulmonary Abnormalities or Neuromuscular disorders

The individual must meet both of the following criteria for approval:

- The individual's condition impairs the ability to clear respiratory secretions;
- Will be less than 12 months of age at the start of the RSV season.

Immunocompromised child

The individual must meet all of the following criteria for approval:

- Is/will be profoundly immunocompromised during the RSV season (e.g., receiving chemotherapy, hematopoietic stem cell or solid organ transplant);
- Will be less than 24 months of age at the start of the RSV season;
- Synagis is prescribed by or in consultation with an immunologist or an infectious disease specialist.

Cardiac transplant

The individual must meet all of the following criteria for approval:

- Has undergone or will undergo cardiac transplantation during the current RSV season;
- Will be less than 24 months of age at the start of the RSV season;
- Synagis is prescribed by or in consultation with a cardiologist, intensivist, or transplant physician.

Duration of Approval: Approve up to maximum 5 monthly doses

For off-season Synagis requests, authorization of one dose per request may be granted if the RSV activity for the requested region is greater than or equal to 10% with rapid antigen testing or greater than or equal to 3% with real-time polymerase chain reaction (PCR) test within two weeks of the intended dose according to the Central Disease Control (CDC) National Respiratory and Enteric Virus Surveillance System (NREVSS).

Dosing Recommendation

The recommended dose is 15 mg/kg of body weight, administered intramuscularly prior to commencement of the RSV season and remaining doses administered monthly throughout the RSV season.

References

1. Synagis® [prescribing information]. Waltham, MA: Sobi.; November 2021.
2. Hamid S, Winn A, Parikh R et al. Seasonality of respiratory syncytial virus – United States, 2017-2023. *MMWR Morbid Mortal Wkly Rep.* 2023;72:355-361
3. Committee on Infectious Diseases and Bronchiolitis Guidelines Committee. Technical report. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics.* 2014;134(2):e620-638.
4. Respiratory Syncytial Virus. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds). Red Book: 2021-2024 Report of the Committee of Infectious Diseases. 32nd Edition, Itasca, IL: American Academy of Pediatrics; 2021.
5. Robinson KA, Odelola OA, Saldanha IJ. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. *Cochrane Database Syst Rev.* 2016;7:CD007743. doi: 10.1002/14651858.CD007743.pub6.
6. American Academy of Pediatrics. Updated guidance: Use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the 2021-2022 RSV season. Updated December 17, 2021. Available at: <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/>. Accessed on August 11, 2023.
7. American Academy of Pediatrics. Updated guidance: Use of palivizumab prophylaxis to prevent hospitalization from severe respiratory syncytial virus infection during the 2022-2023 RSV season. Updated November 22, 2022. Available at: <https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/interim-guidance-for-use-of-palivizumab-prophylaxis-to-prevent-hospitalization/#:~:text=RSV%20activity%20in%20the%20United,there%20can%20be%20regional%20variation.> Accessed on August 11, 2023.
8. Midgley CM, Haynes AK, Baumgardner C, et al Determining the seasonality of respiratory syncytial virus in the United States: The impact of increased molecular testing. *JID.* 2017;216:345-355.
9. Ambrose CS, Steed LL, Brandon M, et al. National and regional modeling of distinct RSV seasonality thresholds for antigen and PCR testing in the US. *J Clin Virol.* 2019;120:68-77.
10. Beyfortus™ injection [prescribing information]. Swiftwater, PA/ Södertälje, Sweden: Sanofi-Pasteur/AstraZeneca; July 2023.
11. Jones JM, Duttra KEF, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. *MMWR*; 2023;72:34:920-925. Available at: <https://www.cdc.gov/mmwr/volumes/72/wr/pdfs/mm7234a4-H.pdf>. Accessed on: September 5, 2023.
12. ACIP and AAP recommendations for Nirsevimab. August 15, 2023. Available at: <https://publications.aap.org/redbook/resources/25379?autologincheck=redirected>. Accessed on: September 5, 2023.
13. Caserta MT, O'Leary ST, Munoz FM, Ralston SL and the Committee on Infectious Diseases. Palivizumab prophylaxis in infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. *Pediatrics.* 152;1:e2023061803.
14. The Centers for Disease Control and Prevention. Limited availability of nirsevimab in the United States – Interim CDC recommendations to protect infants from respiratory syncytial virus (RSV) during the 2023-2024 respiratory virus season. Published October 23, 2023. Available at: <https://emergency.cdc.gov/han/2023/han00499.asp>. Accessed on: October 24, 2023.